A detailed history of Rhumbline Advisers transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 92,589 shares of CLDX stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,589
Previous 96,480 4.03%
Holding current value
$2.33 Million
Previous $3.57 Million 11.9%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$32.06 - $44.56 $124,745 - $173,382
-3,891 Reduced 4.03%
92,589 $3.15 Million
Q2 2024

Aug 01, 2024

SELL
$32.76 - $42.56 $67,158 - $87,248
-2,050 Reduced 2.08%
96,480 $3.57 Million
Q1 2024

May 09, 2024

BUY
$35.22 - $51.88 $792,731 - $1.17 Million
22,508 Added 29.61%
98,530 $4.14 Million
Q4 2023

Feb 08, 2024

SELL
$22.61 - $40.65 $14,741 - $26,503
-652 Reduced 0.85%
76,022 $3.02 Million
Q3 2023

Nov 09, 2023

BUY
$25.45 - $37.46 $79,429 - $116,912
3,121 Added 4.24%
76,674 $2.11 Million
Q2 2023

Aug 08, 2023

SELL
$30.29 - $38.28 $11,237 - $14,201
-371 Reduced 0.5%
73,553 $2.5 Million
Q1 2023

May 11, 2023

BUY
$34.78 - $47.43 $70,116 - $95,618
2,016 Added 2.8%
73,924 $2.66 Million
Q4 2022

Feb 14, 2023

BUY
$27.78 - $45.38 $42,586 - $69,567
1,533 Added 2.18%
71,908 $3.21 Million
Q3 2022

Nov 10, 2022

BUY
$22.7 - $37.57 $122,965 - $203,516
5,417 Added 8.34%
70,375 $1.98 Million
Q2 2022

Aug 11, 2022

BUY
$20.5 - $37.33 $261,149 - $475,546
12,739 Added 24.4%
64,958 $1.75 Million
Q1 2022

May 12, 2022

BUY
$27.64 - $39.32 $66,225 - $94,210
2,396 Added 4.81%
52,219 $1.78 Million
Q4 2021

Feb 10, 2022

BUY
$35.68 - $56.27 $19,909 - $31,398
558 Added 1.13%
49,823 $1.93 Million
Q3 2021

Nov 12, 2021

BUY
$28.95 - $55.99 $244,048 - $471,995
8,430 Added 20.64%
49,265 $2.66 Million
Q2 2021

Aug 05, 2021

BUY
$20.71 - $35.37 $845,692 - $1.44 Million
40,835 New
40,835 $1.37 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.18B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.